Skip to main content

Market Overview

Recap: Quest Diagnostics Q1 Earnings



Shares of Quest Diagnostics (NYSE:DGX) rose 0.0% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 300.00% year over year to $3.76, which beat the estimate of $3.71.

Revenue of $2,720,000,000 higher by 49.29% from the same period last year, which beat the estimate of $2,640,000,000.


Quest Diagnostics raised first-half sales guidance from $4.85B-$5.15B to $5.00B-$5.20B.

Conference Call Details

Date: Apr 22, 2021

Time: 08:30 AM

ET Webcast URL:

Price Action

52-week high: $134.71

52-week low: $92.55

Price action over last quarter: Up 6.76%

Company Description

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.


Related Articles (DGX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at